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INTRODUCTION AND OBJECTIVES:
To provide standardization as prostate MRI becomes increasingly utilized, the Prostate Imaging-Reporting and Data System (PIRADS) was developed and has been modified to its latest version (v2). Using biopsy outcome as the standard, we examined the predictive accuracy of a PIRADS 4 or 5 read for clinically significant (Gleason 7+) PCa in a blinded fashion.
METHODS: We reviewed our prospectively maintained database of consecutive men who underwent prostate MRI prior to biopsy between September 2014 and December 2015. A proportionally representative sample (based on the original clinical PIRADS v2 interpretation) was selected for re-examination (n¼32). The prostate MRIs for these patients were de-identified and were loaded by a blinded third party. Four radiologists of varying levels of experience independently interpreted all prostate MRI, blinded to all clinical information. An 00 overread 00 was defined as a PIRADS 4 or 5 read with biopsy result of benign prostate or Gleason 6 PCa. An 00 under-read 00 was defined as a PIRADS 1-3 read with resulting biopsy result of Gleason 7+ PCa.
RESULTS: The distribution of accuracy is provided in Table 1 . Accurate interpretation ranged from 56% (18/32) to 75% (24/32), and the differences among the radiologists were not significant (p¼0.48). 
Preliminary singleinstitution data has suggested a benefit of prostate MRI and fusion biopsy (FBx) in evaluation of patients considered for active surveillance (AS). We aim to determine the utility of MRI/FBx for confirmation of AS candidacy and identify predictors of Gleason upgrading in a multiinstitutional cohort of patients.
METHODS: A retrospective review was completed at five tertiary referral centers to identify patients with Gleason 3+3¼6 or Gleason 3+4¼7 prostate cancer with PSA < 15 who underwent 3T prostate MRI and confirmatory FBx between 2012-2015. MRI regions of interest (ROI) were reported according to PIRADSv2 criteria. The primary outcome was Gleason score upgrading on targeted sampling when compared to pre-FBx standard 12-core biopsy (SBx). Univariate and multivariate analysis of variance were performed to identify clinical, imaging, and pathologic characteristics independently associated with Gleason score upgrading on fusion biopsy.
RESULTS: A total of 225 patients were identified meeting inclusion criteria, of which 209 (93%) had Gleason 3+3¼6 and 16 (12%) had Gleason 3+4¼7 disease on SBx. Confirmatory FBx resulted in Gleason score upgrading within the targeted ROI in 90 patients (40%). Detailed patient demographics and pathologic characteristics are depicted in Table 1 . FBx did not miss any high risk PCa, while identifying 10 patients (12.5%) with high risk disease missed on SBx alone. Patient age (p¼0.003), pre-fusion biopsy PSA (p¼0.020), initial standard 12-core Gleason score (p¼0.070), prostate volume (p¼0.003), and PI-RADSv2 classification (p¼0.056) were found to be associated with confirmatory FBx upgrading on univariate analysis. Multivariate analysis demonstrated a significant and independent association of patient age (p¼0.001), pre-fusion biopsy PSA (p¼0.006), prostate volume (p¼0.020), and PI-RADSv2 classification (p¼0.050) with FBx upgrading.
CONCLUSIONS: Confirmatory FBx improves risk stratification of patients considering AS. Age, pre-FBx PSA, prostate volume, and PIRADSv2 classification were independently associated with Gleason score upgrading on confirmatory FBx. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e95
